News & information

Keep up with the latest from R&D Partners

R&D Partners – The Rise of FSP Outsourcing in Drug Development

 

The rise of FSP (Functional Service Provider) outsourcing in drug development is revolutionizing the pharmaceutical and biotechnology industries. This has occurred largely due the need to be more agile than ever in launching new medicines at speed, without sacrificing quality.

This growing development reflects the industry’s changing approach to optimizing resources and expertise. Biopharma companies are increasingly turning to specialized service providers to help them minimize any difficulties in drug development, so this trend is predicted to go from strength to strength. Because of FSP outsourcing, there are now unique opportunities in the pharmaceutical industry to bring innovative therapies to market more efficiently and cost-effectively.

As the FSP market size is expected to reach a compound annual growth rate (CAGR) of 8.7% by the end of the decade, we explore what this means for the business of drug development.

 

What is FSP?

FSPs are companies that are contracted by other organizations for specific functions. The FSP model sees organizations partnering with specialized service providers to manage certain areas of the drug development process. Previously, the full-service model would involve outsourcing the entire project to a single contract research organization (CRO) or contract manufacturing organization (CMO).

This new approach allows pharmaceutical companies to tap into specialized expertise and resources, while maintaining greater control and flexibility in the development of new drugs.

 

Why is FSP on the rise?

Here are some key factors contributing to the rise of FSP outsourcing in drug development.

 

Cost efficiency

FSP outsourcing can be a cost-effective option for pharmaceutical companies, as the companies can choose to outsource only the particular functions or tasks that require specialized knowledge. This flexibility can help in reducing spend, as they don’t have to commit to a comprehensive outsourcing arrangement.

It also gives biotechnology and biopharma companies access to technologies they don’t have within their organization. This avoids having to make a long-term investment in tech products they wouldn’t otherwise make use of or get enough value from.

 

Specialized expertise

Drug development is a complex and highly regulated process involving various specialized tasks, such as clinical trials, regulatory affairs, data management, and pharmacovigilance. FSP providers often have a high level of ability in these areas, leading to an excellent quality of work and better results.

If these particular skills aren’t present within the permanent workforce, companies have the benefit of being able to utilize them without needing to allocate any budget to hiring permanent internal specialists.

 

Resource scalability

FSPs allow pharmaceutical companies to be flexible and scale their resources up or down, as needed. During pressured times of work fluctuation or in response to bottlenecks, they can hire FSP providers for specific projects or phases of drug development. They can adjust their outsourcing strategy based on each project’s requirements and pipeline changes.

 

Focus on core competencies

By outsourcing non-core functions to FSP providers, pharmaceutical companies can focus their in-house resources and skillsets on core research and development activities. This can help to accelerate project timelines and bring new drugs to market more quickly.

It also means there are fewer vendor relationships to manage, as they are consolidated within the FSP. This relationship maintenance in itself can take away valuable time over the course of developing a new product. FSPs can additionally support relationships with sites by minimizing disruption if there is a high turnover of clinical research associates (CRAs).

 

Global reach

FSP providers often have a global presence, enabling pharmaceutical companies to tap into a broader network of resources, expertise, and patient populations for clinical trials and regulatory approvals. This helps to maximize opportunities for profitable growth across new markets and territories.

 

Risk mitigation

Sharing responsibilities with specialized FSP providers can help to limit the risks associated with drug development. This is because these providers often have an in-depth understanding of regulatory requirements and compliance issues, which can significantly slow down the launch of new drugs.

 

Technological advances

Increasingly sophisticated technology and data analytics have made it easier for pharmaceutical companies to collaborate with FSP providers for data management, real-world evidence generation, and other critical functions.

 

Regulatory support

FSP providers can assist pharmaceutical companies in navigating complex regulatory landscapes. FSPs should know everything about regulatory affairs, so they can help with each stage of submissions and ensure compliance with evolving government requirements.

 

Strategic partnerships

Many pharmaceutical companies establish long-term strategic partnerships with FSP providers, going on to collaborate over multiple projects. When they find FSPs they can trust, this further streamlines the entire process, as companies can be more reactive and quickly call upon high-quality providers as soon as the need arises.

 

COVID-19 impact

The COVID-19 pandemic undoubtedly accelerated the adoption of FSP outsourcing with the new challenges it posed, as organizations had to balance new ways of working. This occurred for a number of reasons:

  • Companies began to seek flexible and remote work options for certain functions, such as clinical trial monitoring and data analysis, in order to have access to a global talent pool
  • As organizations ran trials for new diagnostics, vaccines and treatments, they were able to place the required focus on these projects while keeping ongoing studies running separately
  • The use of remote monitoring, such as Electronic Clinical Outcome Assessment (eCOA), quickly became commonplace as the collection of patient information went digital-first

 

Click Here to learn about the benefits of partnering with an FSP like R&D Partners.

 

Partner with our functional service provider team

Supporting pharmaceutical and biotechnology companies at R&D Partners

At R&D Partners, we can support you with integrating customized FSP models. We specialize in helping life science organizations with their strategic staffing needs, with over 200 years of combined experience among our expert team. We pride ourselves on our professional and passionate approach, high level of expertise and ability to help deliver targeted results for specific client projects.

Get in touch today to find out how we can support your business and get answers to any queries you may have.

SHARE IT
Facebook
Twitter
LinkedIn
Email